Andy Parker predicts phase one readout from solid tumor safety expansion cohorts within 12-15 months (by October 2027).
“And in the next twelve to fifteen months, we'll end up with the phase one readout from the solid tumors in terms of the safety expansion cohorts.”
→ Read the source episode
Our resolution criterion
disputableStepPharma releases phase one solid tumor safety expansion cohort readout data
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
Laurent Levy predicts Nanobiotics will report randomized phase two lung cancer trial results before H1 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.